A Single Polymorphic Residue in Humans Underlies Species-specific Restriction of HSV-1 by the Antiviral Protein MxB

Overview

Journal bioRxiv

Date 2023 Jul 3

PMID 37398298

Authors

Avraham Bayer

Stephanie J Child

Harmit S Malik

Adam P Geballe

Affiliations

Soon will be listed here.

Abstract

Importance: Herpesviruses present a major global disease burden. Understanding the host cell mechanisms that block viral infections as well as how viruses can evolve to counteract these host defenses is critically important for understanding viral disease pathogenesis, and for developing therapeutic tools aimed at treating or preventing viral infections. Additionally, understanding how these host and viral mechanisms adapt to counter one another can aid in identifying the risks of, and barriers to, cross-species transmission events. As highlighted by the recent SARS-CoV-2 pandemic, episodic transmission events can have severe consequences for human health. This study reveals that the major human variant of the antiviral protein MxB inhibits the human pathogen HSV-1, whereas human minor variants and orthologous MxB genes from even closely related primates do not. Thus, in contrast to the many antagonistic virus-host interactions in which the virus is successful in thwarting the defense systems of their native hosts, in this case the human gene appears to be at least temporarily winning at this interface of the primate-herpesviral evolutionary arms race. Our findings further show that a polymorphism at amino acid 83 in a small fraction of the human population is sufficient to abrogate MxB's ability to inhibit HSV-1, which could have important implications for human susceptibility to HSV-1 pathogenesis.

References

Carpentier K, Esparo N, Child S, Geballe A . A Single Amino Acid Dictates Protein Kinase R Susceptibility to Unrelated Viral Antagonists. PLoS Pathog. 2016; 12(10):e1005966. PMC: 5079575. DOI: 10.1371/journal.ppat.1005966. View

Ohainle M, Helms L, Vermeire J, Roesch F, Humes D, Basom R . A virus-packageable CRISPR screen identifies host factors mediating interferon inhibition of HIV. Elife. 2018; 7. PMC: 6286125. DOI: 10.7554/eLife.39823. View

Karczewski K, Francioli L, Tiao G, Cummings B, Alfoldi J, Wang Q . The mutational constraint spectrum quantified from variation in 141,456 humans. Nature. 2020; 581(7809):434-443. PMC: 7334197. DOI: 10.1038/s41586-020-2308-7. View

Melen K, Julkunen I . Nuclear cotransport mechanism of cytoplasmic human MxB protein. J Biol Chem. 1998; 272(51):32353-9. DOI: 10.1074/jbc.272.51.32353. View

Ladner C, Yang J, Turner R, Edwards R . Visible fluorescent detection of proteins in polyacrylamide gels without staining. Anal Biochem. 2004; 326(1):13-20. DOI: 10.1016/j.ab.2003.10.047. View

Wertheim J, Smith M, Smith D, Scheffler K, Kosakovsky Pond S . Evolutionary origins of human herpes simplex viruses 1 and 2. Mol Biol Evol. 2014; 31(9):2356-64. PMC: 4137711. DOI: 10.1093/molbev/msu185. View

Goujon C, Moncorge O, Bauby H, Doyle T, Barclay W, Malim M . Transfer of the amino-terminal nuclear envelope targeting domain of human MX2 converts MX1 into an HIV-1 resistance factor. J Virol. 2014; 88(16):9017-26. PMC: 4136259. DOI: 10.1128/JVI.01269-14. View

Crameri M, Bauer M, Caduff N, Walker R, Steiner F, Franzoso F . MxB is an interferon-induced restriction factor of human herpesviruses. Nat Commun. 2018; 9(1):1980. PMC: 5958057. DOI: 10.1038/s41467-018-04379-2. View

Busnadiego I, Kane M, Rihn S, Preugschas H, Hughes J, Blanco-Melo D . Host and viral determinants of Mx2 antiretroviral activity. J Virol. 2014; 88(14):7738-52. PMC: 4097781. DOI: 10.1128/JVI.00214-14. View

10.

Schoggins J . Interferon-Stimulated Genes: What Do They All Do?. Annu Rev Virol. 2019; 6(1):567-584. DOI: 10.1146/annurev-virology-092818-015756. View

11.

Khandelia P, Yap K, Makeyev E . Streamlined platform for short hairpin RNA interference and transgenesis in cultured mammalian cells. Proc Natl Acad Sci U S A. 2011; 108(31):12799-804. PMC: 3150880. DOI: 10.1073/pnas.1103532108. View

12.

Fribourgh J, Nguyen H, Matreyek K, Alvarez F, Summers B, Dewdney T . Structural insight into HIV-1 restriction by MxB. Cell Host Microbe. 2014; 16(5):627-638. PMC: 4252739. DOI: 10.1016/j.chom.2014.09.021. View

13.

Sironi M, Biasin M, Cagliani R, Gnudi F, Saulle I, Ibba S . Evolutionary analysis identifies an MX2 haplotype associated with natural resistance to HIV-1 infection. Mol Biol Evol. 2014; 31(9):2402-14. DOI: 10.1093/molbev/msu193. View

14.

Betancor G . You Shall Not Pass: MX2 Proteins Are Versatile Viral Inhibitors. Vaccines (Basel). 2023; 11(5). PMC: 10224399. DOI: 10.3390/vaccines11050930. View

15.

Underdown S, Kumar K, Houldcroft C . Network analysis of the hominin origin of Herpes Simplex virus 2 from fossil data. Virus Evol. 2017; 3(2):vex026. PMC: 5617628. DOI: 10.1093/ve/vex026. View

16.

Kane M, Rebensburg S, Takata M, Zang T, Yamashita M, Kvaratskhelia M . Nuclear pore heterogeneity influences HIV-1 infection and the antiviral activity of MX2. Elife. 2018; 7. PMC: 6101944. DOI: 10.7554/eLife.35738. View

17.

Matreyek K, Wang W, Serrao E, Singh P, Levin H, Engelman A . Host and viral determinants for MxB restriction of HIV-1 infection. Retrovirology. 2014; 11:90. PMC: 4213484. DOI: 10.1186/s12977-014-0090-z. View

18.

Vasudevan A, Bahr A, Grothmann R, Singer A, Haussinger D, Zimmermann A . MXB inhibits murine cytomegalovirus. Virology. 2018; 522:158-167. DOI: 10.1016/j.virol.2018.07.017. View

19.

Collins R, Brand H, Karczewski K, Zhao X, Alfoldi J, Francioli L . A structural variation reference for medical and population genetics. Nature. 2020; 581(7809):444-451. PMC: 7334194. DOI: 10.1038/s41586-020-2287-8. View

20.

Boutell C, Cuchet-Lourenco D, Vanni E, Orr A, Glass M, McFarlane S . A viral ubiquitin ligase has substrate preferential SUMO targeted ubiquitin ligase activity that counteracts intrinsic antiviral defence. PLoS Pathog. 2011; 7(9):e1002245. PMC: 3174244. DOI: 10.1371/journal.ppat.1002245. View